
(This Dec.13 story has been corrected to remove reference to Sanofi in the fifth paragraph)
(Reuters) - Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.